Cel Sci Corporation (CVM)

[cvmibelieve]

The main thing I found note worthy in the 10Q was the NEW deliberate wording of the study goal, which is now the "primary endpoint" and is no longer the 298.

Since there is no longer any dosing of Multikine the only thing they can do at this point is to continue to (track patient survival).

Very important...when 298 was the message Cel Sci was tracking "patient deaths" NOW they are tracking Patient "SURVIVAL" when you track survival ... death numbers are irrelevant

"continue to track patient survival until it can be determined if the primary endpoint of the study will be met"

The primary endpoint (survival) will be determined "AFTER" a total of 298 events (deaths) have occurred in the two main comparator arms of the study and have been recorded in the study database.

The pivot in new terminology and focus is on the "primary endpoint" which is: (10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. SOC alone)

Order of operations says that you cannot evaluate if you have met the "primary endpoint" (survival) UNTIL (after) the final 298 events (deaths) occur.